Look at the Lids Website
Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U. S.
IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology in order to revolutionize treatment for patients, starting with eye care, today announced the launch of the “ Look at the particular Lids ” disease education campaign for Demodex blepharitis, a common cover margin ailment that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage eye treatment professionals to screen for Demodex blepharitis in all eye care individuals to identify plus diagnose the disease sooner. The strategy will be unveiled at the 2022 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago and the American School of Optometry (AAOpt) Yearly Meeting inside San Diego. “ Consider the Lids ” features real Demodex blepharitis patients and will include educational tools and resources for vision care professionals, including an informative website ( www.LookattheLids.com ), social media channels, webinars, launch events, and interactive activities in the Academy conferences.
“We’re thrilled in order to launch this truly unique disease education campaign with regard to Demodex blepharitis, a pervasive and damaging eye illness that is commonly overlooked, ” said Aziz Mottiwala, Chief Commercial Officer of Tarsus. “The goal of this particular campaign is to support eye care professionals so they can confidently and more frequently diagnose patients. Tarsus is committed to elevating eyelid health, and we look forward to bringing more awareness to this disease that adversely impacts so many sufferers. ”
Approximately 25 mil eye treatment patients in the United States have Demodex blepharitis, the lid margin disease characterized by eyelid inflammation, redness, plus ocular irritation. The disease is caused by an infestation of Demodex mites, the most common ectoparasite found upon humans. Collarettes, the cylindrical waxy debris composed of mite waste products and eggs on the eyelashes, are the particular pathognomonic sign of Demodex blepharitis, plus can be identified by an attention care professional when a patient looks down during a slit lamp exam. One hundred percent associated with patients along with collarettes have Demodex blepharitis.
“ Demodex blepharitis, though extremely common, can masquerade as ocular allergies or dry eye condition since the symptoms are often similar, ” said Eric Donnenfeld, MD, Cornea, Laser Cataract & Refractive Surgeon from OCLI Vision in New York. “The disease can be missed unless an eyesight care professional is specifically looking for the presence of collarettes, the particular sure indication of Demodex blepharitis. Fortunately, identifying collarettes is a simple step achieved by asking a patient to look straight down during a routine eye examination. I see Demodex in my practice daily, and I am encouraged that there is a campaign that will bring more visibility to this disease and assist other clinicians in their efforts in order to improve eyelid health. ”
At both Academy meetings, “ Look with the Covers ” will possess an online exhibit booth featuring a custom photo activation that allows eyes care experts to showcase their commitment to eyelid health simply by adding their own eyelid photo to a real-time updated video wall. The marketing campaign will also feature launch occasions and interactive activities, all designed to provide disease schooling.
“It is remarkable how many patients I discover who have got Demodex just by examining their lashes when they look lower during a regular eye test, ” stated Selina McGee, OD, FAAO, CEO associated with BeSpoke Eyesight in Oklahoma. “This disease is often hiding in plain sight, plus without properly screening for it, many individuals go undiagnosed. Demodex can cause damage and discomfort when left untreated, and I’m excited to be a part of the campaign designed to increase the identification plus diagnosis of this very common illness. ”
Eye care specialists can subscribe to the Collarette Coalition email list and be the first to receive the latest news and information on Demodex blepharitis on www.LookattheLids.com . The website also allows eye care professionals in order to submit their own photos and videos to the ‘Lid Gallery. ’ Additionally, they can share their very own Demodex blepharitis stories with the eye care community on social media by using #LookattheLids and following plus tagging @lookatthelids on Instagram and Twitter .
In concert with the advertising campaign – and as part associated with Tarsus’ dedication to education and learning and innovation in vision care – the company may provide a donation to both the particular American School of Ophthalmology Foundation and the American Academy of Optometry Foundation.
About Demodex Blepharitis
Blepharitis is really a common lid margin disease that is seen as a eyelid margin swelling, redness plus ocular discomfort. Demodex blepharitis is triggered by a good infestation of Demodex mites, the majority of common ectoparasite found upon humans and accounts for over two-thirds associated with all blepharitis cases. Demodex blepharitis may affect as many as 25 million Americans based on an extrapolation from the Titan study indicating 58% of patients presenting to U. S. attention care clinics have collarettes, a pathognomonic sign of Demodex infestation, plus that at least 45 million people annually visit an eye care clinic. Demodex blepharitis can have a significant clinical burden and negative impact upon patients’ daily lives. The particular Titan study also showed that current management equipment, such as tea tree oil and cover wipes, are ineffective at treating Demodex blepharitis. Currently, there are no FDA-approved treatments for Demodex blepharitis.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceutical drugs, Inc. applies proven technology and new technology to revolutionize treatment regarding patients, starting with eye treatment. Tarsus is usually advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus will be studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is the novel therapeutic which has demonstrated positive results in two pivotal trials intended for therapy of Demodex blepharitis, and of which a New Drug Application has been submitted in order to the Circumstance. S. Food & Drug Administration (FDA). TP-03 is also being developed for the treatment of Meibomian Gland Disease, and currently being studied in a Phase 2a clinical trial. In addition , Tarsus is developing TP-05, an oral, non-vaccine therapeutic to get the avoidance of Lyme disease, which is currently being studied within a Phase 1b medical trial.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are usually not historical facts, may constitute “forward-looking statements. ” These claims include statements regarding the potential market size for TP-03, future activities and Tarsus’ plans pertaining to as well as the anticipated benefits of the product candidates including TP-03 and TP-05, the timing, objectives and results of the particular clinical trials, anticipated regulatory and development milestones, plus the quotations of Tarsus’ management and consultants. The words, without limitation, “believe, ” “contemplate, ” “continue, ” “could, ” “estimate, ” “expect, ” “intend, ” “may, ” “might, ” “plan, ” “potential, ” “predict, ” “project, ” “should, ” “target, ” “will, ” or “would, ” or the negative of these terms or even other comparable expressions are intended to identify forward-looking claims, although not almost all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements because a result of various important factors. Further, presently there are other risks plus uncertainties that could cause actual results to differ from those set forth within the forward-looking statement and they are detailed from time to period in the reports Tarsus files using the Securities and Exchange Commission, including Tarsus’ Form 10-K meant for the year ended December 31, 2021 filed on March 14, 2022 and the most recent Form 10-Q quarterly filing filed with the SEC on August 11, 2022, each associated with which Tarsus incorporates simply by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However , brand new risk aspects and uncertainties may emerge from time to time, and it is usually not possible to predict just about all risk elements and questions. Accordingly, readers are cautioned not to place undue reliance on these types of forward-looking claims. Any forward-looking statements contained in this particular press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, plus Tarsus particularly disclaims any kind of obligation in order to update any forward-looking declaration, whether as a result of new information, future events or otherwise.
Sr. Director, Corporate Communications
[email protected] possuindo
Investor Get in touch with:
Head of Investor Relations
[email protected] apresentando
A photo accompanying this announcement is obtainable at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a55faf1-5038-425d-85da-0325acdb2c0a